(Q35078215)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21609447%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

title

Long-term benefits of omalizumab in a patient with severe non-allergic asthma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21609447%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21609447%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Roberto Piro

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21609447%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

author name string

Nicola Facciolongo

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21609447%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Claudia Castagnetti

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21609447%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Anna Simonazzi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21609447%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Luigi Zucchi

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21609447%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

publication date

24 May 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21609447%20AND%20SRC:MED&resulttype=core&format=json

Allergy, Asthma & Clinical Immunology

2 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21609447%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21609447%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21609447%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

page(s)

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21609447%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 2.0 Generic

2 February 2020

copyright license

start time

24 May 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Efficacy and Safety of Subcutaneous Omalizumab vs Placebo as Add-on Therapy to Corticosteroids for Children and Adults With Asthma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126749

"Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126749

A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126749

Anti-IgE for chronic asthma in adults and children

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126749

Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126749

Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and nonatopic subjects with asthma.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126749

Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126749

Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving omalizumab (Xolair) therapy.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126749

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126749

Elevation of total serum immunoglobulin E is associated with asthma in nonallergic individuals

27 September 2018

1 reference

12 December 2020

Beneficial effects of treatment with anti-IgE antibodies (Omalizumab) in a patient with severe asthma and negative skin-prick test results

1 reference

12 December 2020

Measuring quality of life in asthma

1 reference

12 December 2020

Omalizumab decreases nonspecific airway hyperresponsiveness in vitro

1 reference

12 December 2020

Identifiers

DOI

10.1186/1710-1492-7-9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21609447%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

2 February 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21609447%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

PubMed publication ID

21609447

1 reference